You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for New Drug Application (NDA): 022048


✉ Email this page to a colleague

« Back to Dashboard


NDA 022048 describes TRIESENCE, which is a drug marketed by Harrow Eye and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the TRIESENCE profile page.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 022048
Tradename:TRIESENCE
Applicant:Harrow Eye
Ingredient:triamcinolone acetonide
Patents:2
Pharmacology for NDA: 022048
Medical Subject Heading (MeSH) Categories for 022048
Suppliers and Packaging for NDA: 022048
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048 NDA Novartis Pharmaceuticals Corporation 0078-0897 0078-0897-78 1 BLISTER PACK in 1 CARTON (0078-0897-78) / 1 VIAL, GLASS in 1 BLISTER PACK / 1 mL in 1 VIAL, GLASS
TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048 NDA Harrow Eye, LLC 82667-800 82667-800-01 1 BLISTER PACK in 1 CARTON (82667-800-01) / 1 VIAL, GLASS in 1 BLISTER PACK / 1 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVITREALStrength40MG/ML (40MG/ML)
Approval Date:Nov 29, 2007TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Dec 17, 2029Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:Mar 10, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF OPHTHALMIC DISORDERS
Patent:⤷  Sign UpPatent Expiration:Mar 10, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:VISUALIZATION DURING VITRECTOMY PROCEDURES

Expired US Patents for NDA 022048

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Harrow Eye TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.